Adherium Secures AU$7.52 million Capital Raising to Fund U.S. Strategy
Adherium Limited (ASX: ADR) has unveiled a capital raising initiative targeting up to AU$7.52 million, structured as an institutional placement alongside an accelerated pro rata non-renounceable entitlement offer. The retail component of the entitlement offer is scheduled to open on 23 February 2026, with a target of up to AU$0.82 million, and will allow eligible retail shareholders to participate on the same terms.
Proceeds will be directed toward scaling commercial initiatives, with a primary focus on expanding the Company’s Remote Patient Monitoring channel in the United States and progressing discussions around value-based care contracts with U.S. insurers. The funding supports key near-term milestones, including the release of final iCARE clinical study data and the continued build-out of a second major revenue pathway through insurer-aligned care models. The raise reflects institutional confidence in Adherium’s commercial strategy and accelerating market traction.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Adherium Secures AU$7.52 million Capital Raising to Fund U.S. Strategy
Adherium Limited (ASX: ADR) has unveiled a capital raising initiative targeting up to AU$7.52 million, structured as an institutional placement alongside an accelerated pro rata non-renounceable entitlement offer. The retail component of the entitlement offer is scheduled to open on 23 February 2026, with a target of up to AU$0.82 million, and will allow eligible retail shareholders to participate on the same terms.
Proceeds will be directed toward scaling commercial initiatives, with a primary focus on expanding the Company’s Remote Patient Monitoring channel in the United States and progressing discussions around value-based care contracts with U.S. insurers. The funding supports key near-term milestones, including the release of final iCARE clinical study data and the continued build-out of a second major revenue pathway through insurer-aligned care models. The raise reflects institutional confidence in Adherium’s commercial strategy and accelerating market traction.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au